文献速递妇科

2018 FIGO分期系统对宫颈癌的预后价值

Prognostic value of the 2018 FIGO staging system for cervical cancer.
PubMed 文献 · Gynecol Oncol · 2022-03-26

该研究基于丹麦2005—2018年4461例宫颈癌患者,将2009 FIGO分期重新转换为2018 FIGO分期并比较预后分层能力。41.4%的病例发生分期迁移,2018分期改善了I期和IV期的区分能力,但将盆腔或腹主动脉旁淋巴结阳性患者统一归入IIIC期导致该期内生存率明显异质。

要点

  • 41.4%的宫颈癌病例因2018 FIGO分期发生分期迁移。
  • 2018分期改善了I期和IV期的区分能力。
  • 淋巴结阳性患者统一归入IIIC期导致该期内生存率明显异质。

核心结论

  • 2018 FIGO分期系统对I期和IV期的区分能力有所改善。
  • 将所有盆腔或腹主动脉旁淋巴结阳性患者归入IIIC期导致该期内生存率明显异质。
  • 对于浸润深度3—5 mm、水平扩散>7 mm且伴LVSI的FIGO 2018 IA2期鳞状细胞癌,淋巴结评估被证明是必要的。

研究设计与样本

  • 通过丹麦妇科癌症数据库识别2005—2018年丹麦诊断的4461例宫颈癌患者,并将2009 FIGO分期重新转换为2018 FIGO分期。

主要发现

  • 41.4%的病例发生分期迁移,其中20.1%归因于IIIC期的引入,76.2%归因于I期内肿瘤大小标准的细化,3.7%归因于使用影像学表现定义IV期。
  • 除IA2、IIA2、IIIA和IIIB期外,所有分期的5年总生存率均有所提高。
  • 将2009 IB1期重新分期为2018 FIGO分期后,产生了显著的分期分配变化。
  • 在浸润深度3—5 mm且水平扩散>7 mm的鳞状细胞癌中,观察到LVSI与LNM之间存在关联(p=0.03)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the prognostic performance of the FIGO 2009 and FIGO 2018 staging systems for cervical cancer (CC) in regards to risk stratification, survival and treatment outcome. METHODS: A total of 4461 CC patients diagnosed in Denmark during 2005-2018 were identified through the Danish Gynaecological Cancer Database and restaged from the 2009 FIGO to the 2018 FIGO staging system. 5-year survival estimates were made for each group. Also, association between lymphovascular space invasion (LVSI) and lymph node metastasis (LNM) was assesed for tumors with a horizontal spread >7 mm and depth of invasion ≤5 mm. RESULTS: Overall, stage migration was observed in 41.4% of our cases due to the introduction of stage IIIC (20.1%), refined tumor size criteria within stage I (76.2%), and use of radiological findings to define stage IV (3.7%). 5-year overall survival increased for all stages except IA2, IIA2, IIIA and IIIB. Restaging of 2009 IB1 to 2018 FIGO resulted in significant stage allocations. Furthermore, an association between LVSI and LNM was observed in squamous cell carcinomas with a depth of invasion of 3-5 mm and a horizontal spread >7 mm (p = 0.03). CONCLUSION: The 2018 FIGO staging system provided improved discriminatory ability for stage I and IV. Grouping all patients with positive pelvic or paraortal lymph nodes to stage IIIC led to pronounced heterogenous survival rates within these stages. Lymph node assessment was proven imperative in FIGO 2018 IA2 squamous cell carcinomas with a depth of invasion of 3-5 mm, a horizontal spread >7 mm and LVSI.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Mohamud A, Høgdall C, Schnack T, et al. Prognostic value of the 2018 FIGO staging system for cervical cancer. Gynecol Oncol. 2022. PMID: 35346512. doi:10.1016/j.ygyno.2022.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。